ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PRM Proteome Sciences Plc

3.25
0.18 (5.86%)
12 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.18 5.86% 3.25 2.50 4.00 - 148,375 16:35:22
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 7.78M 1.33M 0.0045 6.82 9.06M
Proteome Sciences Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome Sciences was 3.07p. Over the last year, Proteome Sciences shares have traded in a share price range of 2.97p to 8.50p.

Proteome Sciences currently has 295,182,056 shares in issue. The market capitalisation of Proteome Sciences is £9.06 million. Proteome Sciences has a price to earnings ratio (PE ratio) of 6.82.

Proteome Sciences Share Discussion Threads

Showing 157451 to 157474 of 157475 messages
Chat Pages: 6299  6298  6297  6296  6295  6294  6293  6292  6291  6290  6289  6288  Older
DateSubjectAuthorDiscuss
12/4/2024
16:51
I note that cjp's loan with interest accruing is now £11.235m & prm has an mcap just over £9m
elpirata
12/4/2024
12:35
normal service resumed, zilch trades, not a sausage

STRONG DONT BUY

elpirata
11/4/2024
11:09
The "top coins" rubbish below is nothing to do with me - I would delete it if I could

I say goatherd thats a bit strong isnt it? We all know pools has a tendency to wander down the garden path but 'rubbish?' Will you be banning the avatar next?

elpirata
10/4/2024
15:11
And may I ask we vote against any of these being reinstated for another 12 months.tia.
peverill
10/4/2024
15:08
Should tank about 16.25.
peverill
10/4/2024
14:48
I'll stick to looking at the share price and long term chart, thanks all the same.
barry evans
10/4/2024
14:45
Unfortunately, you should pay far more attention, as your hatred for everything PRM completely blinds you. Proteome Sciences have stated AD license deals publicly. You can find out where yourself.

STRONG BUY

wasjobber
10/4/2024
13:48
Odd that they should make no mention of this in either the Profit warning or those dire results and downbeat supporting statements, no?
barry evans
10/4/2024
13:29
Proteome Sciences have only recently received these important new patent grants. The area is complex and just because biomarkers are currently being used by other companies, it does not mean they won't require a license from Proteome Sciences moving forward.

I think Proteome Sciences will get license deals (and associated back payments) for Alzheimers disease and cancer soon.

wasjobber
10/4/2024
12:43
the olde fishing expedition bait given another outing I note our patented biomarkers may prove critical in development of novel diagnostic tests opening up additional licensing opportunities

As of April 2024, there are at least eight different Alzheimer’s blood biomarker tests on the market...

& prm nowhere to be seen, we've been down this alleged patents rabbit hole many times before

elpirata
10/4/2024
12:19
Maeby?


vbrs
Michael Cera

barry evans
10/4/2024
12:17
‘Maybe’ btw.
monte1
10/4/2024
12:15
I should imagine he is feeling a right Charlie today.


Randox_Girl

Posts: 3

Price: 3.00

Strong Buy

Good news coming 4 Apr 2024 21:39

Proteome Sciences will announce good news with their results

barry evans
10/4/2024
12:04
Mabey deliberately negative, looking for a bid?
goggin
10/4/2024
11:24
There are very, very few crumbs of comfort to be taken from the results.

Line after line it is repeated that each and every sales sector was 'Challenging'

As for the US start up, perhaps the timing couldnt have been more wrong?

"It was a challenging year in our service business in 2023. As in previous years, the US is by far our most significant market in terms of biopharma companies who outsource their proteomic services to Contract Research Organisations ("CROs") such as Proteome Sciences. Unfortunately, the biopharma market especially in the US was marked by employee layoffs in 2023. According to Fierce Biotech, a company that provides news, analysis and data relating to the biotech sector, biopharma layoffs were 57% up in 2023. This has been confirmed by other Life Science provider companies in their public reporting. The significantly reduced level of financing in biopharma resulted in workforce reductions affecting 187 organisations in 2023. We were in contact and discussing projects with 38 of these that were primarily focused in proteomic pre-clinical and clinical research. Projects were either cancelled before samples were shipped, or significantly delayed pending future financing rounds. This seriously affected our ability to win business."

barry evans
10/4/2024
11:12
We knew the number would be poor as it was flagged earlier, and we also knew that the expences of establishing a presence in America would be high. For myself I am pleased that we are in our biggest market.
I am hopeful of the upcomibg stroke test and the real potential of Alzimers especially after the anounced reserch going on in Oxford. In addition the development of new products provides some comfort to me.

wellhonedhutch
10/4/2024
10:13
Someone been on the crack pipe over the other thread.
peverill
10/4/2024
10:08
It is quite sobering to think that there is actually a person IRL that has created the avatars pool2 and wasjobber.
monte1
10/4/2024
10:03
59704 see 59703
barry evans
10/4/2024
10:02
wasjobber,

Thermo have been a long term partner of Proteome Sciences for 15 years, but I agree it'll be good to see Thermo taking a more prominent position. After reading the RNS this morning, the future looks brighter than ever.

You've already mentioned what I think is probably the most significant RNS statement:-

"It's very interesting that PRM are now openly stating that their patented Alzheimer's and cancer biomarkers may be critical to new diagnostics and treatment moving forward.

STRONG BUY"

It's very significant for Proteome Sciences to say that.

The value of these biomarkers will be considerable and will project PRM into the £100 millions plus market cap. with ease.

I think you are now correct, we are at a pivotal moment for the share price and investors buying now will achieve significant returns, possibly quicker than some may think.

pools2
10/4/2024
09:18
Grow up! It was a catastrophic performance with the business having gone badly backwards, there is no other way of looking at it.
barry evans
10/4/2024
09:15
It looks like Thermo are getting more involved with PRM.

"We continue to innovate in chemistry and will be working on ancillary products to add new functionality for TMTproTM enabled studies through a sponsored research project."

wasjobber
10/4/2024
09:01
Riiiiiiiiiichard?
barry evans
10/4/2024
08:49
Absolutely pitiful.
monte1
Chat Pages: 6299  6298  6297  6296  6295  6294  6293  6292  6291  6290  6289  6288  Older

Your Recent History

Delayed Upgrade Clock